Pulmonary Health Benefits of Asparagus racemosus against Common Cold and Asthma

The common cold, the most common human viral disease, is characterized by a self-limiting upper respiratory tract infection. It is caused by over 200 different respiratory viruses, notably rhinoviruses (30–80% of cases), and represents a global threat with significant economic burden. Studies have shown that rhinoviruses are the primary triggers of asthma exacerbations, responsible for about 70% of adult and 80% of paediatric cases, leading to significant morbidity and healthcare burden. The social and economic impact of these diseases is prevalent all over the globe and thus highlights the need for efficient and cost-effective therapies. Conventional treatments for cold and asthma focus primarily on symptomatic relief and bronchodilation but lack antiviral efficacy and often carry side effects. This chapter investigates the complex aetiology, epidemiology, pathology, and management of the common cold, with an emphasis on its relationship to asthma and the potential therapeutic applications of Asparagus racemosus. A. racemosus , known as Shatavari in popular culture, a perennial herbaceous climbing shrub of the Asparagaceae family, acts as a powerhouse in both traditional and modern pharmacological systems. The rich source of phytoconstituents of A. racemosus makes it an attractive choice for managing inflammatory disease caused by virus or bacterial infection. As the common cold and asthma are some of the inflammatory conditions induced by potential pathogens of humans, the application of medicinal herbs such as Shatavari can be an effective choice for disease management. Dyslipidemia and cardiovascular diseases (CVDs) continue to be important issues in global health; thus, finding better, safer treatments is crucial. Promising as a natural substitute for traditional lipid-regulating medications, the famous Ayurvedic herb Asparagus racemosus (Shatavari) has shown substantial cardioprotective and lipid-lowering properties. The anti-inflammatory, antioxidant, nitric oxide–modulating, and cholesterol biosynthesis–inhibiting actions of Shatavari are due to its abundance of bioactive chemicals, including saponins, flavonoids, alkaloids, and polyphenols. By influencing lipid metabolism and important enzyme pathways like HMG-CoA reductase and LCAT, Shatavari lowers total cholesterol, triglyceride, and LDL levels while increasing HDL levels, according to both experimental and preclinical research. Atherosclerosis prevention, endothelial function improvement, and protection against ischemia-reperfusion injury are all aspects of its cardioprotective properties. To confirm its effectiveness and safety in controlling dyslipidemia and cardiovascular disorders, large-scale clinical trials are required, even if early human investigations show promising results. Recent developments in formulation tactics, such as delivery systems based on nanoparticles and polyherbal combinations, have the ability to enhance the bioavailability and therapeutic effect of Shatavari. To make it more accessible in mainstream medicine, though, issues like standardization, quality control, and regulatory clearance need to be resolved. This chapter offers a thorough analysis of Shatavari’s cardioprotective and lipid-lowering effects, showcasing its possible involvement in the creation of pharmacological and nutraceutical therapies for heart health. In order to fully realize its therapeutic potential, future research should center on clinical validation, mechanistic studies, and new formulations.